---
schema_version: "secwatch.filing_event.v1"
accession: "0001645113-23-000045"
form_type: "8-K"
ticker: "NVCR"
cik: "0001645113"
company_name: "NovoCure Ltd"
filed_at: "2023-07-27T23:59:59+00:00"
generated_at: "2026-06-13T00:34:24.111435+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.9
calibrated_materiality_score: 0.9
confidence: "high"
source: SEC EDGAR
---

# Novocure Q2 net revenue $126M (-11% YoY); phase 3 LUNAR NSCLC trial meets primary endpoint

## Summary
- Net loss $57.4M ($0.54 per share); adjusted EBITDA -$27.2M; active patients 3,571.
- LUNAR trial: median OS 13.2 months TTFields+standard vs 9.9 months standard alone (HR=0.74, p=0.035).
- Revenue decline largely due to $13.4M reduced collections from previously denied U.S. claims.
- Prescriptions up 13% to 1,556; U.S., Germany, Japan contributed 981, 204, and 92 respectively.
- PANOVA-3 (pancreatic) DMC recommends proceeding to final analysis; LUNAR-2 trial IDE accepted by FDA.

## SEC filing metadata
- accession: 0001645113-23-000045
- form_type: 8-K
- ticker: NVCR
- cik: 0001645113
- company_name: NovoCure Ltd
- filed_at: 2023-07-27T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.9
- calibrated_materiality_score: 0.9
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1645113/000164511323000045/0001645113-23-000045-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1645113/000164511323000045/nvcr-20230727.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001645113-23-000045
- JSON: https://secwatch.observer/filing/0001645113-23-000045.json
- Plain text: https://secwatch.observer/filing/0001645113-23-000045.txt

## Key facts
- Earnings Releases
  NovoCure Ltd reported the quarter ended June 30, 2023 results: revenue $126.1 million, net income $57.4 million, EPS $0.54.
  - Period: the quarter ended June 30, 2023
  - Revenue: $126.1 million
  - Net income: $57.4 million
  - EPS: $0.54
  - Result: reported results
  source text: 30, 2023. A copy of the press release is attached as Exhibit 99.1. --- EX-99.1 (EX-99.1) --- Novocure Reports Second Quarter 2023 Financial Results Quarterly net revenues of $126 million with 3,571 active patients on therapy as of June 30, 2023 Phase 3 LUNAR trial in non-small cell lung cancer met primary and key secondary survival endpoints, the first of four
  evidence_url: https://www.sec.gov/Archives/edgar/data/1645113/000164511323000045/0001645113-23-000045-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.